Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory

被引:9
作者
Bakke, H
Setek, TN
Huynh, PN
Haugen, IL
Hoiby, EA
Holst, J
Aaberge, IS
Haneberg, B
机构
[1] Norwegian Inst Publ Hlth, Div Infect Dis Control, NO-0403 Oslo, Norway
[2] Univ Oslo, Inst Pharm, Dept Microbiol, N-0316 Oslo, Norway
关键词
mucosal vaccines; Neisseria meningitidis; outer membrane vesicles (OMVs);
D O I
10.1016/j.vaccine.2003.11.040
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mice immunised intranasally with Multiple doses of outer membrane vesicles (OMVs) from group B meningococci developed antibody responses that depended on the interval between doses. High levels of antibodies in saliva and extracts of faeces were induced within 4 weeks after an OMV vaccine had been given at weekly intervals, whereas the antibody responses in these samples were negligible when given four times at 1-day or 1-h intervals, or as one large dose. Only modest responses were obtained in serum after 4 weeks, however, whether the vaccine had been given repeatedly at any schedule, including the 1-week interval, or as one dose. On the other hand, two large doses given 8 weeks apart induced booster antibody responses in both serum and secretions that matched the responses from a second series of the four smaller doses. Intranasal immunisations may thus stimulate immunological memory more rapidly in secretions than in serum. In order to secure adequate systemic responses by a minimum of doses, nasal vaccines should therefore be given at intervals longer than 4 weeks, in harmony with the intervals recommended for injectable vaccines. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2278 / 2284
页数:7
相关论文
共 21 条
[1]   SCID-HU MICE IMMUNIZED WITH A PNEUMOCOCCAL VACCINE PRODUCE SPECIFIC HUMAN-ANTIBODIES AND SHOW INCREASED RESISTANCE TO INFECTION [J].
AABERGE, IS ;
MICHAELSEN, TE ;
ROLSTAD, AK ;
GROENG, EC ;
SOLBERG, P ;
LOVIK, M .
INFECTION AND IMMUNITY, 1992, 60 (10) :4146-4153
[2]   Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance [J].
Bakke, H ;
Lie, K ;
Haugen, IL ;
Korsvold, GE ;
Hoiby, EA ;
Næss, LM ;
Holst, J ;
Aaberge, IS ;
Oftung, F ;
Haneberg, B .
INFECTION AND IMMUNITY, 2001, 69 (08) :5010-5015
[3]  
Berstad AKH, 1997, VACCINE, V15, P1473
[4]   Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice [J].
Dalseg, R ;
Wedege, E ;
Holst, J ;
Haugen, IL ;
Hoiby, EA ;
Haneberg, B .
VACCINE, 1999, 17 (19) :2336-2345
[5]   Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers [J].
Drabick, JJ ;
Brandt, BL ;
Moran, EE ;
Saunders, NB ;
Shoemaker, DR ;
Zollinger, WD .
VACCINE, 1999, 18 (1-2) :160-172
[6]  
FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67
[7]   Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans [J].
Haneberg, B ;
Dalseg, R ;
Wedege, E ;
Hoiby, EA ;
Haugen, IL ;
Oftung, F ;
Andersen, SR ;
Naess, LM ;
Aase, A ;
Michaelsen, TE ;
Holst, J .
INFECTION AND IMMUNITY, 1998, 66 (04) :1334-1341
[8]   INDUCTION OF SPECIFIC IMMUNOGLOBULIN-A IN THE SMALL-INTESTINE, COLON-RECTUM, AND VAGINA MEASURED BY A NEW METHOD FOR COLLECTION OF SECRETIONS FROM LOCAL MUCOSAL SURFACES [J].
HANEBERG, B ;
KENDALL, D ;
AMERONGEN, HM ;
APTER, FM ;
KRAEHENBUHL, JP ;
NEUTRA, MR .
INFECTION AND IMMUNITY, 1994, 62 (01) :15-23
[9]  
HANEBERG B, 2002, EXPERT REV VACCINES, V2, P227
[10]   Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines [J].
Haugan, A ;
Dao, PXT ;
Glende, N ;
Bakke, H ;
Haugen, IL ;
Janakova, L ;
Berstad, AKH ;
Holst, J ;
Haneberg, B .
VACCINE, 2003, 22 (01) :7-14